and increase the proportion of patients who respond to immunotherapy. The phase 2 trial will recruit patients with advanced melanoma that can’t be treated with surgery who are refractory to or ...

The study also helps to understand why when melanoma spreads to other organs, leading to metastases, it often develops resistance to conventional immunotherapy. In addition, Midkine reprograms ...